Trial Profile
Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TACo-BEAT-MBM
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 10 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.